Pulse Biosciences, Inc. (PLSE) News
Follow Pulse Biosciences, Inc. (PLSE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Pulse Biosciences Initiated at Buy by BTIG
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:37 AM UTC
L
BTIG initiates coverage of Pulse Biosciences with Buy rating, $70 price target
BTIG initiated coverage on Pulse Biosciences's stock with a rating of Buy and a price target of $70.00.The price target implies an upside of 32.9% from the Sep 22 close of $52.69.Key takeaways from the analyst noteInnova
EQUITY | Sep 23, 2026, 10:27 AM UTC
L
Pulse Biosciences completes 100-patient PRECISE-BTN enrollment; first patient reaches 12-month follow-up
Pulse Biosciences completed enrollment of 100 patients in the PRECISE-BTN study and the first patient finished the 12-month follow-up.Key Highlights:Original SEC Filing: PULSE BIOSCIENCES, INC. [ PLSE ] - 8-K - Sep. 15,
REGULATION | Sep 15, 2026, 01:03 PM UTC
L
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN c
NEWS | Sep 15, 2026, 11:03 AM UTC
L
Pulse Biosciences initiated at Buy; Freedom Capital Markets sets $73 target
Freedom Capital Markets initiated Pulse Biosciences at Buy and announced a $73.00/share price target, according to Benzinga ratings actions. (TradingView News)
EQUITY | Sep 09, 2026, 12:37 PM UTC
L
Pulse Biosciences grants equity inducement awards to two new employees
Pulse Biosciences announced its Board’s Compensation Committee granted equity awards to two new employees as equity inducement awards under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:00 AM UTC
M
Veeva, Revolution Medicines, Pulse Biosciences flagged as overbought
Veeva Systems reported better-than-expected second-quarter results and raised FY27 guidance above estimates, while Revolution Medicines said the FDA approved Rasonque for metastatic pancreatic adenocarcinoma. Pulse Biosc
REGULATION | Aug 27, 2026, 12:46 PM UTC
L
PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on t
PLSE Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $35 from $30 and keeps an Outperform rating on the shares. Preliminary evidence suggests nsPFA has a better safety and efficacy
EQUITY | Jul 28, 2026, 12:11 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC